About this trial
This is a prospective, parallel group, open-label, multi- center, randomized study to assess two accelerated rehabilitation programs for use with the InSpace device in the treatment of full thickness Massive, Irreparable Rotator Cuff Tears (MIRCTs) performed during an arthroscopic procedure.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
The subject has signed the IRB approved Informed Consent Form (ICF) specific to this study prior to enrollment
Is male or female ≥ sixty-five (65) years of age
Measuring ≥ 5 cm in diameter
Involving ≥ two tendons
Disqualifiers
Known allergy to the device material (copolymer of PLA (poly (lactic acid) and -ε-caprolactone)
Severe gleno-humeral or acromio-humeral arthritis
Full thickness cartilage loss as seen on MRI
History within the past 5 years of anterior or posterior shoulder subluxation or dislocation as determined by history, examination, or radiographic findings
Trial design
Parallel
Treatments tested in this trial
InSpace Subacromial Tissue Spacer
DeviceRotator Cuff Tear Treatment
Treatment groups
Trial outcomes
Primary outcomes
Change in American Shoulder and Elbow (ASES) Score
This is a subject self-report questionnaire and Investigator assessment questionnaire. The subject portion collects information on activities of daily living (i.e., 10 questions). The Investigator assessment portion documents ROM (forward elevation/flexion, external rotation, internal rotation, cross-body adduction), signs, strength, and instability. ASES minimal clinical important difference (MCID) and substantial clinical benefit (SCB) have been previously described for the ASES score in patients undergoing rotator cuff repair as 11.1 and 17.5, respectively. Change in American Shoulder and Elbow Surgeons (ASES) Score will be expressed as the percentages demonstrating a minimal clinical important difference (MCID; ASES ≥ 11.1) and the substantial clinical benefit (SCB; ASES ≥ 17.5) in ASES from baseline at Month 12. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome).
Secondary outcomes
Safety Assessment
• Safety will be evaluated by type, frequency, severity, and relatedness of adverse events to study intervention at each follow-up visit through Month 24
Change in Western Ontario Rotator Cuff (WORC) Score
Change in WORC Score from baseline. Minimum value: 2,100, Maximum value: 0 (with a lower score indicating a better outcome). This is a subject self-report questionnaire that is a disease-specific Quality of Life Measurement Tool specifically designed to evaluate quality of life in persons with pathology of the rotator cuff. It is comprised of 21 items in 5 domains (i.e., physical symptoms, sports and recreation, work, lifestyle, emotions).
Change in Constant Score (CS) Outcome Score
Change in CS Outcome Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a self-reported questions as well as Investigator or designee performed assessment of the shoulder. The tool is divided into four subscales: pain, activities of daily living, strength and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder.
Change in EuroQol 5-Dimensions Questionnaire (EQ-5D-5L) Score
Change in EQ-5D-5L Score from baseline. Minimum value: 0, Maximum value: 100 (with a higher score indicating a better outcome). This is a subject self-report questionnaire to measure health-related quality of life (HRQOL). It consists of 5 questions capturing the subject's current health across five dimensions (i.e., mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). It also includes a numerical visual analogue scale (EQ-VAS).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.